MARKET

CTMX

CTMX

CytomX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.53
+0.22
+2.59%
After Hours: 8.53 0 0.00% 18:52 07/10 EDT
OPEN
8.30
PREV CLOSE
8.31
HIGH
8.77
LOW
8.29
VOLUME
404.77K
TURNOVER
--
52 WEEK HIGH
15.44
52 WEEK LOW
3.595
MARKET CAP
391.50M
P/E (TTM)
-5.0941
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CTMX stock price target is 14.30 with a high estimate of 18.00 and a low estimate of 10.00.

EPS

CTMX News

More
Here's Why We're Watching CytomX Therapeutics's (NASDAQ:CTMX) Cash Burn Situation
Simply Wall St. · 12h ago
Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm
Newsfile · 2d ago
ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Reminds CytomX Therapeutics, Inc. Investors of Important Deadline in Securities Class Action – CTMX
NEW YORK, July 02, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytomX Therapeutics, Inc. (NASDAQ: CTMX) between May 17,.
GlobeNewswire · 07/02 19:24
Shareholder Alert: Robbins LLP Reminds Investors CytomX Therapeutics, Inc. (CTMX) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of CytomX Therapeutics, Inc. (NASDAQ: CTMX) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between May 17, 2018 and May
Business Wire · 07/01 22:32
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Grand Canyon Education, Conns, Ryder System, and CytomX and Encourages Investors to Contact the Firm
GlobeNewswire · 07/01 20:00
Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm
New York, New York--(Newsfile Corp. - July 1, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CytomX Therapeutics, Inc. ("CytomX" or the "Company") (NASDAQ:CTMX) of the July 20, 2020 deadline to seek the role of lead
Newsfile · 07/01 14:18
CTMX Investor Update: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against CytomX Therapeutics, Inc. and Encourages Shareholders to Contact the Firm
Newsfile · 06/30 18:00
CytomX Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In CytomX Therapeutics, Inc. To Contact The Firm
Newsfile · 06/29 15:59

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
More

Webull offers kinds of CytomX Therapeutics Inc stock information, including NASDAQ:CTMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTMX stock methods without spending real money on the virtual paper trading platform.